All In Biotech

Drug Trial Radar · NCT07843329

A Trial to See if Daridorexant Can Help Adults and Elderly People With Insomnia Sleep Better During the Night and Function Better During the Day

A Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group Trial to Assess the Efficacy of Daridorexant on Nighttime Symptoms and Daytime Functioning in Adult and Elderly Participants With Insomnia Disorder

Last checked: Nov 19, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 344 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

344

Planned (sponsor's estimate)

Start

Oct 28, 2026

Primary completion

Nov 22, 2027

Study completion Dec 6, 2027

Sponsor

Lead sponsor
Idorsia Pharmaceuticals Ltd.Industry
Sponsor type
Industry
First posted
Sep 28, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this clinical trial is to collect more data about the effect of daridorexant in adults and elderly people with insomnia disorder. The trial aims to find out whether daridorexant can help improve: * how trial participants sleep at night, * how trial participants function the next day. Researchers will compare daridorexant to a placebo (a look-alike inactive substance that contains no active medicine) to understand which effect daridorexant has on total sleep time and next-day functioning. Enrolled participants will: * Take daridorexant 50 mg or placebo once daily for approximately 3 months * Visit the clinic once every month during treatment for checkups and tests * Keep a sleep diary of the number of hours they sleep and how well they sleep * Complete a questionnaire every day about any symptoms of sleepiness during the day and any impact on physical and mental functioning such as energy levels, mood, or ability to concentrate or memorize.

Conditions

  • Insomia Disorder

Interventions

  • DaridorexantDrug

    Daridorexant 50 mg tablets

  • PlaceboDrug

    Matching placebo tablets

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline to Month 3 in Subjective Total Sleep Time (sTST)Time frame: Baseline and Month 3

Locations

9 sites in 1 country. Site status is shown where the registry gives one.

  • Preferred Research Partners Inc.

    Little Rock, Arkansas · Not yet recruiting

  • Synergy San Diego

    Lemon Grove, California · Not yet recruiting

  • Empire Clinical Research

    Pomona, California · Not yet recruiting

  • Teradan Clinical Trials, LLC

    Brandon, Florida · Not yet recruiting

  • Hope Research Network

    Virginia Gardens, Florida · Recruiting

  • Encore Medical Research, LLC - Weston

    Weston, Florida · Not yet recruiting

  • Advanced Respiratory and Sleep Medicince LLC

    Huntersville, North Carolina · Not yet recruiting

  • Eximia Research - NC, LLC

    Raleigh, North Carolina · Not yet recruiting

  • CTI Clinical Research Center

    Cincinnati, Ohio · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.